Axogen, Inc.

Axogen, Inc. announced a definitive agreement to acquire BioCircuit Technologies, Inc. for $200 million in cash. BioCircuit's flagship product, NerveTape, is the first FDA-approved device for sutureless peripheral nerve repair, which Axogen believes will broaden its addressable market and accelerate adoption. The transaction is expected to close in the fourth quarter of 2026. Concurrently, Axogen priced a public offering of 4,910,000 shares of common stock at $42.50 per share, expecting to raise approximately $208.7 million, with net proceeds intended to fund the acquisition.

Axogen, Inc. reported its Q2 2026 financial results, showing revenue growth but a shift to net loss. The company successfully repaid its $69.7 million Credit Facility debt in January 2026, funded by a $133.3 million net proceeds equity offering. For the second quarter, revenues increased to $69.7 million, but the company posted a net loss of $1.5 million, compared to a net income in the prior year. The six-month period saw a net loss of $21.1 million, significantly impacted by a $16.8 million loss on debt extinguishment.

Axogen, Inc. reported strong second quarter 2026 financial results, with revenue increasing 23.1% year-over-year to $69.7 million. The company raised its full-year 2026 revenue guidance to at least 24% growth, targeting $279 million. Despite a GAAP net loss of $1.5 million, adjusted net income grew to $7.3 million, and the company highlighted progress in strategic priorities, including clinical study publications and a minority investment in Trace Biosciences.

Axogen, Inc. reported strong second-quarter 2026 revenue of $69.7 million, a 23.1% increase year-over-year. Despite a GAAP net loss of $1.5 million, the company achieved an adjusted net income of $7.3 million. Axogen also highlighted significant business advancements, including the publication of the REPOSE clinical study, initiation of the Nerve-RESTORE study, and a minority investment in Trace Biosciences. The company reiterated its full-year 2026 financial guidance, expecting at least 24% revenue growth and positive free cash flow.

Axogen, Inc. announced it will release its financial results for the second quarter of 2026 on Wednesday, July 29, 2026. Following the release, Axogen management will host a conference call and webcast for the investment community at 8:00 a.m. ET. Details for participating in the call and accessing the webcast and presentation slides are provided.

Axogen, Inc. announced its participation in the upcoming 2026 Bank of America Global Healthcare Conference. The company's management is scheduled to present on Wednesday, May 13, 2026, at 9:35 AM PT. Interested parties can access a live audio webcast of the presentation through the "Investors" section of Axogen's website.

Axogen, Inc. announced its 2026 Annual Meeting of Shareholders will be held virtually on Tuesday, June 23, 2026. Shareholders will vote on the election of eight directors, the ratification of Deloitte & Touche LLP as the independent auditor, and a non-binding advisory vote on executive compensation. The record date for shareholders entitled to vote is April 24, 2026.

Axogen, Inc. reported a net loss of $(19.6) million for Q1 2026, primarily driven by a $16.8 million loss on extinguishment of debt. This debt repayment of $69.7 million was funded by net proceeds of $133.3 million from a public offering of common stock. The company also saw a 26.6% increase in revenues to $61.5 million and a significant improvement in cash flow from operations.

Axogen, Inc. reported strong first-quarter 2026 financial results, with revenue increasing 26.6% year-over-year to $61.5 million. The company achieved positive adjusted net income of $4.1 million and significantly improved its adjusted EBITDA to $5.7 million. Following this performance, Axogen raised its full-year 2026 revenue guidance to at least 20% growth, targeting $270 million, and expects to be free cash flow positive for the year. The company also strengthened its balance sheet by closing a public offering that generated $133.3 million in net proceeds, which was used to repay a $69.7 million loan facility.